Worldwide Biospatial Market Expected to Grow at 30% Annually, Reaching $1.2 Billion by 2027 – Market Report by DeciBio Consulting

Los Angeles–(working wire) – DeciBio Consulting LLC’s latest Market Report,”DeciBio Spatial Biology Market Report 2022It states that the global biospatial market — driven by steady growth in academia and exponential growth in biopharmaceuticals and CROs, particularly in clinical trials — is expected to reach $1.2 billion by 2027.

This report summarizes the current and future (2022-2027) landscape of spatial biology products and services, with a focus on spatial and multiplex chemistry and methods. Based on primary and secondary research, DeciBio’s databases and tools, and the expertise of DeciBio’s consultants, this report provides quantitative and qualitative assessments of key market segments (eg, technology, customer type, application, plex level). In addition, the report details market drivers (for example, increasing adoption in certain customer segments), drivers (for example, high cost of instruments and reagents), trends (for example, interest in combining spatial transcriptomes with proteins), and profiles. Detailed senior players.

Spatial biology can be defined as the analysis of targeted analyte(s) in tissues in a spatial context (i.e., the expression of a marker in the context of its location within the tissue and/or other markers), primarily driven by multiplex analysis of biomarkers. Academia has been the largest customer segment for spatial biology analysis to date, however, its use in translational research for biopharmaceuticals and clinical trials is increasing as initial studies yield promising results and analytical techniques and pipelines become more accessible and validated. Continuous advances in scalability, standardization, and clinical usefulness are expected to drive growth throughout research and development.

Methodology/Scope of the Report:

Learn more about the DeciBio Spatial Biology Market Report First Edition: Q4 2022

https://www.decibio.com/market-reports/spatial-biology-market

Spatial biology companies are mentioned:

• Upcam

• Genome spatial sharpness

• Advanced Cytodiagnostics (Biotechnology)

• Akoya Biological Sciences

• amber

• Bethel Labs

• Biocare Medical

• bioSyntagma

• Umbrella Biosciences

• Cell IDx (Leica Biosystems)

• silkarta

• Selecta

• Sirpa Research

• Crown of Biological Sciences

• Setiva

• Enzo Life Sciences

• Leading biological sciences

• 10x genomics

• undivided

• ionpath

• labcorp

• Leica Biosystems

• Leica Microsystems

• Lonfur

• Miltenyi Biotec

• nanostring

• NeoGenomics

• United Kingdom

• s² Solution

• Rare

• Ribos Biosystems

• Bioscience solution

• Roche Diagnostics

• Spatial genomics

• Standard BioTools

• Sincel

• Ultivue

• Vector coefficient

• viraset

• Physicol

• vision

• else

Geospatial Market Analysis:

Market drivers

Proactive data generation, advent of immuno-oncology, and improvements (in capabilities, accessibility, flexibility of platforms and chemistries) will spur adoption and use of spatial biospatial technologies and will drive market growth. Technical and insights informed by critical data and driving market value will continue to emerge in the spatial biology industry as analytical capabilities are enhanced by AI-based image analysis algorithms and digital pathology. The interest in – and funding for – spatial technologies and companies will increase the interest of the industry at large in bringing these new tools to market as well.

Market supervisors

There are still barriers to market entry and development in the field of spatial biology. Sufficient potential initial findings in clinical data for spatial signatures are essential for measurable success in clinical adoption. In addition, to ensure market success, clinics need to develop regulatory policies, payer policies, and data platforms that support high platelet tissue analysis. Cost is also a deterrent to implementation because of the high cost per test (up to $5,000 per slide), and bioinformatics costs (eg, up to another $5,000 per slide or more for multiple analyses). Finally, experimental data is necessary to allay scalability concerns, as throughput is still limited (eg, ~20 slices per day for a 3-6-plex mIF, versus 1 slice per day for a 20+ plex). As clinical infrastructure evolves and spatial signatures gain traction, there is a wide window of opportunity and market growth.

About Decibio:

DeciBio Consulting (www.decibio.com) is the leading strategy consulting, market intelligence, and SaaS firm dedicated to accelerating the adoption and impact of technologies that enable precision medicine.

Headquartered in Los Angeles, California, DeciBio serves a global base of clients and customers, ranging from start-ups to Fortune 500 healthcare companies. DeciBio provides consulting services for growth planning, market and opportunity assessment, product and portfolio strategy, customer feedback, technology assessment, and commercial due diligence.